Profilo
Daniel-Adriano Silva was the founder who started Neoleukin Therapeutics, Inc. in 2003, where he held the title of Vice President-Research until 2021.
He obtained an undergraduate degree from Universidad Nacional Autónoma de México.
Precedenti posizioni note di Daniel-Adriano Silva
| Società | Posizione | Fine |
|---|---|---|
| NEUROGENE INC. | Founder | 01/03/2021 |
Formazione di Daniel-Adriano Silva
| Universidad Nacional Autónoma de México | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Daniel-Adriano Silva
